| 摘要 |
<p>The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X- ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01 ± 0.2 (°2θ), measured with a Cu-Kα irradiation (1.54060 â«), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's Disease and other dopamine-related disorders.</p> |
